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ABSTRACT 
 
Two vaccinia virus (VACV) expression systems that contain elements from the 
lactose (lac) and the tetracycline (tet) operons of E. coli were developed to repress the 
expression of a reporter gene, enhanced green fluorescent protein (EGFP), in the presence 
of tet operon inducers.  In the first system, lac and tet operon elements were arranged in a 
gene circuit, and in the presence of increasing concentrations of a lac operon inducer 
(isopropyl-β-D-thiogalactoside, IPTG), EGFP expression increased in a dose dependent 
manner and at high IPTG concentrations, expression reached the same levels as a positive 
control virus.  Importantly, in the presence of increasing concentrations of the tet operon 
inducer (doxycycline, DOX), EGFP expression decreased in a dose dependent manner 
and at high concentrations of DOX, expression was repressed to the degree observed in a 
negative control virus that does not express EGFP.  In the second system, recombinant 
VACVs constitutively expressing six mutant versions of the tet repressor gene (tetR) 
shown to bind tet operators in the presence, but not absence of inducers (reverse tetR 
genes), were developed.  In the presence of tetracyclines (TCs), the recombinant VACVs 
exhibited various degrees of repression of EGFP expression, with increasing 
concentrations of TCs leading to EGFP repression in a dose dependent manner, and in 
some instances, down to the degree observed in a negative control virus.  In light of the 
renewed interest for the use of VACV as vaccine and therapeutic cancer vectors, the 
repressible VACV expression system developed here can be used to tightly regulate 
genes essential for VACV replication, thus functioning as a built-in safety mechanism to 
conditionally control viral replication. 
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1.1.  VACCINATION AND VACCINIA VIRUS 
In 1796, Dr. Edward Jenner demonstrated that protection could be achieved 
against the highly pathogenic variola virus (smallpox virus) by prior infection with a 
related and less pathogenic virus, cowpox virus.  Today, this preventative measure is 
called vaccination.  Between the 19th and 20th centuries, it is theorized that vaccinia 
virus (VACV) replaced cowpox as a result of rudimentary smallpox vaccination practices 
(Fenner and World Health Organization, 1988).  In the 1960s, to finally quell the rampant 
spread of smallpox disease that had up to a 30% case fatality rate (Fenner and World 
Health Organization, 1988), the World Health Organization (WHO) launched the 
smallpox eradication campaign, in which VACV was widely produced and administered 
as a live vaccine.  In 1979, the WHO succeeded in this feat and smallpox virus was 
declared eradicated (Wehrle, 1980, World Health Organization. Global Commission for 
the Certification of Smallpox Eradication, 1980).  To date, there has been no re-
emergence of smallpox and its eradication is considered one of the greatest achievements 
in the history of medicine. 
VACV belongs to the family Poxviridae and has many unique characteristics.  
This large complex virus is roughly 200 × 250 nm in size and consists of a dsDNA 
genome that is about 190 kb with nearly 200 open reading frames (ORFs) (Moss and Earl, 
2001).  Viral replication in VACV is distinctive as its genome encodes its own 
transcription machinery that allows transcription to occur autonomously within the host 
cell cytoplasm, with no evidence of viral gene integration into the host genome (Figure 
1.1).  Additionally, transcription occurs in an ordered cascade of early, intermediate and 
late transcriptional events controlled by specialized VACV promoters.  VACV promoters 
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have two conserved sequence components, the core and the initiator, that differ between 
each temporal promoter.  Early mRNAs are detected 20 min post-infection (PI) and levels 
peak within the first 100 min.  Intermediate mRNAs are detected within 100 min PI and 
peaks at about 2 hr PI.  Late mRNAs are detected at 140 min PI and increase 
continuously for about 48 hr.  Posttranscriptional modifications of viral mRNA such as 
capping and polyadenylation occurs, but there is no RNA splicing as viral mRNA is 
made in the cytoplasm.  Subsequently, viral mRNAs are translated by host ribosomes.  
The assembly of viral genome and proteins occur in viral factories following complex 
morphogenesis and maturation steps that ultimately lead to the generation of new virions.  
Mature virions can stay cell associated, bud, or lyse out of the infected host cells (Moss 
and Earl, 2001).   
 
1.2.  VACCINIA VIRUS AS A VECTOR 
With the eradication of smallpox, VACV became one of the best characterized 
viruses and has gained much attention in the fields of vaccines and cancer therapies.  In 
addition to having a wide mammalian host range, VACV is easy to genetically 
manipulate (Mackett et al., 1982), is able to carry at least 25 kb of heterologous DNA 
while still maintaining its infectivity (Smith and Moss, 1983), and it is able to elicit 
potent humoral and cell-mediated immune responses against heterologous antigens 
(Tartaglia and Paoletti, 1988).  Successful VACV-vectored vaccines have been generated 
(Verardi et al., 2012).  For example, a recombinant VACV vaccine expressing the 
glycoprotein of rabies virus has been used extensively in Europe and North America to 
eradicate sylvatic rabies (Pastoret and Brochier, 1996).  Also, a recombinant VACV-
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vectored vaccine expressing the fusion and hemagglutinin glycoproteins of rinderpest 
virus elicited long-term protective immunity against rinderpest in cattle (Verardi et al., 
2002, Yilma et al., 2003).  VACV vectored human vaccines for human 
immunodeficiency virus (HIV) (Harari et al., 2008, McCormack et al., 2008, Bart et al., 
2008, Garcia et al., 2011, Goepfert et al., 2011), malaria (Sheehy et al., 2011, Sheehy et 
al., 2012), and anthrax (Merkel et al., 2010) are currently undergoing pre-clinical 
evaluation or have reached the stage of human clinical trial testing. 
Another unique characteristic of VACV is its tropism for cancer cells.  VACV has 
a predilection to replicate in cancerous cells that can be exploited as delivery systems 
(e.g., carrying co-stimulatory molecules to induce immune responses to cancer cells) or 
as oncolytic vectors that can lead to the destruction of cancer cells.  Currently, cancer 
immunotherapies against prostate cancer or oncolytic therapies against solid tumors are 
being closely evaluated in clinical trials for efficacy (Verardi et al., 2012).  Furthermore, 
a dual-functioning oncolytic recombinant VACV expressing the co-stimulatory molecule 
granulocyte-macrophage colony-stimulating factor (GM-CSF) is being studied in human 
clinical trials as an “armed” oncolytic therapy against cutaneous melanoma (Mastrangelo 
et al., 1999, Kirn and Thorne, 2009, Breitbach et al., 2011, Guse et al., 2011).   
 
1.3.  SMALLPOX VACCINE 
Despite the eradication of smallpox, there are currently significant concerns that 
may require widespread smallpox vaccination to resume.  For example, one major 
concern is the threat of smallpox as a bio-weaponized pathogen (Breman and Henderson, 
1998).  Unaccounted sources of variola virus may still exist around the globe and 
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contribute to this threat.  Additionally, advancements in genetic engineering may allow 
the laboratory generation of the virus based on published variola virus genomic 
sequences (Massung et al., 1994).  Also, there could be a release of similar or genetically 
engineered poxviruses that are more pathogenic and virulent (Gottschalk and Preiser, 
2005).  Another concern is the natural re-emergence of a smallpox-like disease caused by 
a related virus, such as monkeypox virus (Reynolds et al., 2012).  Monkeypox virus is 
currently endemic in Africa, but a US outbreak in 2003 due to the importation of African 
rodents highlights its potential to re-emerge as a serious public health hazard outside 
Africa (Centers for Disease Control and Prevention (CDC), 2003, Reed et al., 2004).  
Thus, to prepare for these potential risks, the US has a stockpile of a smallpox vaccine 
(Greenberg and Kennedy, 2008, Monath et al., 2004, Nalca and Zumbrun, 2010).   
 
1.4.  ADVERSE EVENTS AND CONTRAINDICATIONS 
The smallpox vaccine used in the US during the smallpox eradication campaign 
(Dryvax, one of the first-generation smallpox vaccines) was prepared from scarified 
lesions on calves and it was very efficacious.  However, a large subset of the population 
is currently deemed contraindicated against live, replication-competent VACV vaccines.  
Individuals that are immunosuppressed (HIV/AIDS, transplant, and cancer patients), have 
(or had) atopic dermatitis and other skin conditions, that are pregnant, or have cardiac 
problems, are especially susceptible to a range of mild to severe adverse events (Casey et 
al., 2005, Lane and Goldstein, 2003, Thomas et al., 2008).  Mild adverse events include 
headache, fever, and pain at the inoculation site.  However, severe adverse events include 
eczema vaccinatum (in which VACV replicates in areas affected or once affected by 
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atopic dermatitis, possibly leading to death), progressive vaccinia (a severe adverse event 
that usually affects those that are immunosuppressed as the virus grows uncontrollably in 
flesh, skin and even bones, and could also lead to a grave outcome), and encephalitis 
(where VACV enters the nervous system, which typically leads to death).  In addition, 
vaccinated individuals can inadvertently inoculate themselves (autoinoculation) or 
inoculate others via contact transmission.  A conservative estimate of individuals in the 
US that fall within this population is about 25% (Kemper et al., 2002).  Affected 
individuals, depending on the severity of complications, can be treated with vaccinia 
immune globulin (VIG) or antiviral agents such as cidofovir, ST-246, and some tyrosine 
kinase inhibitors, but the efficacy of these treatments is questionable (Lane and Goldstein, 
2003, Centers for Disease Control and Prevention (CDC), 2009).   
There have been great strides taken to increase the safety of smallpox vaccines for 
individuals with contraindications (Verardi et al., 2012).  For instance, a second-
generation smallpox vaccine (ACAM2000, a single-clone derivative from the Dryvax 
vaccine) was produced in cell culture.  While ACAM2000 has improved sterility and is 
the current US stockpiled smallpox vaccine, its safety in terms of adverse events was not 
improved.  In another attempt to increase the safety profile of smallpox vaccines, the 
VACV strain Ankara was passaged over 570 times in chick embryo fibroblasts.  The 
resulting virus, named Modified Vaccinia Ankara (MVA), is highly attenuated in 
mammalian hosts.  MVA-BN is a prospective third-generation smallpox vaccine 
developed by the vaccine company Bavarian Nordic that is currently on fast-track human 
clinical trials.  However, the protection afforded by MVA as a smallpox vaccine is 
uncertain since vaccinated individuals were never exposed to smallpox.  Genetic 
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engineering has also been used as a tool for the generation of attenuated VACV strains 
such as NYVAC, derived from the Copenhagen strain in which 18 nonessential genes 
were deleted.  NYVAC is also highly attenuated with a restricted host range.  Although 
these attenuated strains provide a better safety profile, they have numerous limitations.  
In particular, highly attenuated strains may require multiple inoculations to elicit a robust 
immune response, which is not ideal in the event of the emergence of an orthopoxvirus or 
a bioterrorist event (Lane, 2011).  Furthermore, they incur higher costs to propagate and 
manufacture and as oncolytic therapies, highly-attenuated VACV strains would not be 
appropriate, as there is no oncolytic potential in replication-incompetent viruses (Kirn 
and Thorne, 2009).   
 
1.5.  SIGNIFICANCE 
VACV, as a replication-competent virus, has several excellent characteristics that 
make it a powerful smallpox vaccine, as well as a vaccine and therapeutic cancer vector.  
However, adverse events associated with uncontrollable VACV replication must be 
addressed.  Thus, an approach to address this limitation is to develop a repressible system 
to control gene expression in VACV.  The focus of this project is to develop and test 
repressible expression systems in VACV by using elements from the tetracycline (tet) 
and lactose (lac) operon systems of E. coli to control the expression of a reporter gene, 
enhanced green fluorescent protein (EGFP).  A future step would be to place a gene that 
is essential to VACV viral replication under the control of this repressible system, so that 
should an adverse event occur after vaccination or treatment, the expression of the 
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essential gene could be repressed, thereby stopping viral replication and most importantly, 
the adverse event.   
 
1.6.  HYPOTHESIS 
The following specific aims will test two different strategies to develop a 
repressible VACV expression system, so that in the presence of an operon inducer, the 
gene of interest will be repressed (not expressed): 
 
Specific Aim 1:  To develop a repressible VACV expression system assembled via a 
gene circuit with natural repressors from the lac and tet operons.   
 
We will develop a recombinant VACV (vIRG, vaccinia virus lacI/tetR 
Repressible Green fluorescent gene) expressing the natural tetracycline repressor gene 
(tetR) under the control of a constitutive early/late VACV promoter (PE/L), and the lacI 
gene under the control of an engineered PE/L VACV promoter containing a tet operator 
(tetO) sequence (Figure 1.2).  EGFP will be under the control of an engineered late 
VACV promoter (P11) containing a lacO sequence.  In the absence of tetracyclines (TCs), 
the TetR repressor binds to the tetO2 operator sequence and prevents the transcription of 
lacI, allowing the expression of EGFP.  In the presence of TCs, TetR undergoes a 
conformational change and does not bind to the tetO2 sequence, allowing LacI to be 
expressed and to bind to the lacO sequence, preventing the expression of EGFP. 
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Specific Aim 2:  To develop a repressible VACV expression system assembled with 
reverse tet repressor mutants and other elements from the tet operon.   
 
We will develop recombinant VACVs (vRG, vaccinia virus Repressible Green 
fluorescent gene) expressing reverse mutants of tetR (revtetR) under the control of the 
constitutive PE/L promoter, and EGFP under the control of an engineered P11 promoter 
containing a tetO2 sequence.  In the absence of TCs, revTetR does not bind to the tetO2 
operator sequence and allows transcription of EGFP (Figure 1.3).  In the presence of TCs, 
revTetR undergoes a conformational change and binds to the tetO2 sequence, preventing 
the expression of EGFP.   
 
1.7.  THE LACTOSE OPERON 
The lactose (lac) operon is composed of a set of genes that enable prokaryotes to 
use lactose as a carbon source.  The regulatory components of the lac operon include a 
lactose repressor gene (lacI), DNA operator sequences (lacO), and an inducer, such as the 
natural inducer (allolactose) or the synthetic analog isopropyl-1-thio-β-D-galactoside 
(IPTG) (Figure 1.4).  The lacI gene encodes a homotetrameric LacI repressor protein.  
Each monomer contains a DNA binding domain, a hinge region, and an inducer binding 
region.  There are three different lacO sequences (O1, O2, and O3), with O1 having the 
highest affinity for LacI.  In 1961, Jacob and Monod elucidated the mechanism of the lac 
regulatory system in E. coli (Jacob and Monod, 1961).  In this system, E. coli will use 
glucose as its primary carbon source.  In this case, LacI is expressed constitutively at low 
levels and negatively controls genes within the lac operon by binding to operator 
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sequences within their independent promoters, thereby leading to the repression of genes 
that encode β-galactosidase (LacZ), permease (LacY), and acetyl-transferase (LacA).  
However, in the absence of glucose and in the presence of lactose, inherent signals will 
initiate the induction of the lac operon.  First, lactose becomes converted to its isomer, 
allolactose, which then binds LacI, inducing a conformational change so that LacI no 
longer binds to the operator sequences (Lewis, 2005, Wilson et al., 2007).  RNA 
polymerase is then able to bind to the promoter regions that overlap the operators and 
allow the transcription of the genes involved in lactose metabolism (Lewis, 2005, Wilson 
et al., 2007).   
 
1.8.  ALLOLACTOSE ANALOGS 
In the history of genetics, the lac operon system was one of the first and best 
studied genetic systems.  The main way to study the induction of the lac operon was to 
measure the induced expression of the enzyme β-galactosidase.  Before the 1950s, the 
only known methods of measuring β-galactosidase activity were laborious and there was 
a need for a more efficient assay.  Thus, one of the pioneers in the field of genetics, 
Joshua Lederberg, collaborated with chemists to synthesize a substrate for β-
galactosidase.  One colorless and inexpensive substrate, O-nitrophenyl-β-D-galactosidase 
(ONPG), was catalyzed by β-galactosidase into a yellow product that could be 
quantitated using a colorimeter.  However, ONPG was not an inducer of the system 
(Müller-Hill, 1996).  In a quest to find an inducer that activated the lac operon without 
being metabolized by β-galactosidase, Jacob and Monod also collaborated with chemists 
to synthesize new inducers.  Of all analogs synthesized, methyl-1-thio-β-D-galactoside 
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(TMG) and isopropyl-1-thio-β-D-galactoside (IPTG) were tested and found to be strong 
inducers without being metabolized.  IPTG was the strongest inducer and when high 
concentrations of IPTG (5 mM) were used, β-galactosidase was induced in prokaryotes 
within 3 min (Müller-Hill, 1996).  Today, IPTG is commonly used in lac inducible 
expression systems in vitro and in vivo to initiate transcription of genes of interest.   
 
1.9.  USING THE LACTOSE OPERON TO CONTROL GENE EXPRESSION 
The lac system can also be used as a tool to express genes of interest and it has 
been adapted for use both in vitro and in vivo.  In 1987, Hu and Davidson successfully 
developed an inducible system in mammalian cells (mouse L cells), using a plasmid 
containing a reporter gene, chloramphenicol acetyltransferase (CAT), under the control of 
an engineered early promoter from the Simian Virus 40 (SV40) containing a synthetic 
lacO analog sequence and using IPTG (synthetic allolactose analog) to induce CAT 
expression (Hu and Davidson, 1987).  Similarly, Brown et al. studied a lac inducible 
system in HeLa cells, in which IPTG was sufficient to induce the expression of CAT 
(Brown et al., 1987).  Cronin et al. adapted the lac system to transgenic mice, allowing 
the inducible expression of a reporter gene in mice receiving 2 mg/ml of IPTG in 
drinking water (Cronin et al., 2001).  More relevant to this project, Fuerst et al. adapted 
the lac operon to VACV by generating inducible recombinant VACVs that contained a 
reporter gene (β-galactosidase) under the control of a late VACV promoter (P11) with a 
synthetic lacO placed immediately downstream (Fuerst et al., 1989).  The maximal 
expression of β-galactosidase in cell culture was induced with 5 mM IPTG (Fuerst et al., 
1989).   
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1.10.  THE TETRACYCLINE OPERON 
Transposon Tn10 of bacteria confers resistance to TCs.  The regulatory 
components of the tet operon include a tetracycline repressor gene (tetR), operator 
sequences (tetO), and an inducer (TCs) (Figure 1.5).  The tetR gene encodes a 
homodimeric TetR repressor protein, where each monomer contains a DNA binding 
domain, a hinge region, and an inducer binding region.  There are two different DNA 
operator sequences, tetO1 and tetO2, with tetO2 having the highest affinity for TetR.  In 
the absence of TCs, TetR autoregulates its expression and negatively controls the genes 
within the tet operon by binding to the tetO sequences that overlap the tet operon 
promoters, thereby leading to the repression of genes that encode TetR and the anti-porter 
transmembrane protein complex (TetA) (Hillen and Berens, 1994).  In the presence of 
TCs, TetR undergoes a conformational change and no longer binds to the operator 
sequences (Hillen and Berens, 1994).  RNA polymerase is then able to bind to the 
promoter regions, allowing the expression of TetA, which aids in the efflux of TCs. 
 
1.11.  TETRACYCLINE DRUG CLASS DERIVATIVES 
TCs are produced by microbes and are known to inhibit translation of other 
prokaryotes to establish a territorial advantage (Greenwald et al., 2001).  The primary 
mechanism of action of TCs is to selectively block the acceptor site (A-site) of 
prokaryotic ribosomes, thus preventing the linkage of a new amino acid to the nascent 
polypeptide chain and ultimately leading to demise of the cell.  The tet operon is an 
adaptive genetic mechanism that leads to TC removal so that prokaryotes can resist its 
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negative effects.  TC derivatives have been synthesized in which drugs within this class 
share the same backbone and differ mostly in functional groups (Greenwald et al., 2001).  
Of the drugs within this class, the synthetic TCs minocycline and doxycycline (DOX) are 
widely used in medicine, animal health, and agriculture.  However, due to multi-drug 
resistance, newer derivatives such as glycylcyclines are being investigated in vitro and in 
vivo.  Another tetracycline widely used in prokaryotic expression systems is 
anhydrotetracyline (ATC), which has increased affinity for TetR and minimal 
antibacterial activity.  
 
1.12.  USING THE TETRACYCLINE OPERON TO CONTROL GENE 
EXPRESSION 
Like the lac operon, the tet operon has been used to generate inducible systems to 
control the expression of a gene of interest.  In 1988, Gatz and Quail first adapted the tet 
operon to tobacco plant cells by cotransfecting a plasmid expressing the reporter gene 
CAT under the control of the cauliflower mosaic virus (CaMV) 35S promoter with two 
tetO2 sites, and another plasmid expressing tetR under the constitutive control of CaMV 
35S. 
In a design of a new mammalian inducible system, Gossen et al. randomly 
mutagenized the tetR gene and screened for mutants that yielded the reverse phenotype in 
the presence of DOX.  One reverse tetR mutant characterized contained the amino acid 
mutations E71K, D95N, L101S, and G102D (Gossen et al., 1995).  Then, a reverse 
tetracycline transactivator (rtTA) was generated by fusing the reverse tetracycline 
repressor gene (revtetR) with a transcriptional activator (TA) from the VP16 gene of 
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herpes simplex virus.  In the presence of TCs, rtTA binds to the tet responsive element 
(TRE), a modified early CMV promoter that lacks strong enhancer elements (PminCMV) 
and contains seven repeats of tetO2, promoting transcription of a gene of interest.  This 
TC-inducible system, referred to as the Tet-On system, became a useful tool for inducible 
control of gene expression in eukaryotic cells and transgenic mice.   
In 2000, Urlinger et al. wanted to improve the original rtTA system as it was not 
very sensitive to DOX and had a high basal level of transcriptional activity in the absence 
of DOX (Urlinger et al., 2000).  The rtTA gene was subjected to direct and random 
mutagenesis and six novel mutants (with two to five amino acid changes) that exhibited 
the reverse TetR phenotype were obtained.  Mutant rtTA-S3 (T26A and D95G) resulted 
in somewhat lower background levels of expression, but in the presence of inducer a 
reporter gene (luciferase) was expressed at lower levels than the original rtTA.  Mutant 
rtTA-S2 (E19G, A56P, D148E, and H179R) had a similar activation potential as rtTA, 
but a significantly lower background activity.  The mutational contributions in rtTA-S2 
were explored by generating mutants rtTA-19/56 (E19G and A56P) and rtTA-148/179 
(D148E and H179R).  rtTA-19/56 had a stringent reverse phenotype and minute 
background activity, while mutant rtTA-148/179 was found to have lost the reverse 
phenotype.  To increase the sensitivity of the system to low concentrations of DOX, 
rtTA-19/56R mutants were grown in media containing 10 ng/ml DOX (less than the 
initial dose used of 10 µg/ml) and subjected to additional mutagenesis.  Mutant rtTA-M1 
(S12G, E19G, and A56P) was recovered with increased sensitivity to DOX and a 
stringent reverse phenotype.  The mutant rtTA-M2 was generated to have enhanced 
activation and high sensitivity to DOX, which had a combination of mutations from 
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rtTA-148/179R and rtTA-M1.  rtTA-M2 had stringent reverse phenotype, low 
background expression properties, and a higher sensitivity towards DOX, and is currently 
a useful tool for inducible control of gene expression, especially in transgenic mice.  
However, a tet system utilizing the VP16 transactivator with a minimal CMV promoter 
would not function in VACV, as VACV transcription is driven by inherent VACV 
promoters.   
Other revTetR mutants were also explored by Scholz et al. with the goal to find 
the minimum number of amino acids required to reverse the phenotype of TetR in E. coli 
(Scholz et al., 2004).  The tetR gene was randomly mutagenized and selected using a TC-
inducible β-galactosidase expression system where in the absence of inducer, revTetR 
cannot bind to its operator and therefore allows expression of the reporter gene, while in 
the presence of inducer, revTetR represses the expression of β-galactosidase.  This 
system was adapted to be dependent on ATC, a TC that does not confer antibiotic activity.  
A total of 41,000 mutants were screened, of which 112 mutants exhibited the revTetR 
phenotype.  Ultimately, two different revTetR mutants having a single amino acid 
mutation (L17G or V99E) were found.  Both revTetR mutants resulted in the expression 
of approximately 90% β-galactosidase activity in the absence of the inducer (ATC) and 
only about 3% β-galactosidase activity in the presence of the inducer.  
In 2000, Traktman et al. developed TC-inducible VACVs by inserting a tetO 
operator sequence between the transcriptional and translational start sites of VACV genes, 
enabling their expression to be tightly regulated by TCs (Traktman et al., 2000).  
Traktman and others have used the TC-inducible system as a tool for regulation of 
specific VACV genes, thereby leading to a better understanding of basic biological 
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properties of VACV.  Weber, Verardi et al. (unpublished data) used a VACV TC-
inducible system developed in the Verardi Lab for a more practical application as a built-
in safety mechanism for VACV based on the inducible expression of interferon-γ (IFN-γ).  
The IFN-γ gene acts as a safety gene in vivo when expressed by VAVC, attenuating the 
virus by more than a million-fold.  Immunodeficient mice inoculated with high doses of 
VACV constitutively expressing IFN-γ are able to rapidly and completely clear infection 
(Legrand et al., 2005).  In this new application of the inducible system, TetR (the 
repressor) is constitutively expressed and binds to an operator (tetO2) placed downstream 
of a VACV promoter (Weber et al., 2007), blocking transcription and expression of the 
IFN-γ gene.  Thus, in the absence of TCs, VACV replicates normally, eliciting full 
immune responses and retaining its oncolytic potential.  When complications arise or are 
suspected, TC treatment causes TetR to undergo a conformational change so that it no 
longer binds to the operator.  This unblocks the promoter and allows expression of IFN-γ, 
resulting in complete clearance of the virus.  Since this inducible built-in safety 
mechanism is based on the expression of a cytokine (IFN-γ), which has the potential to 
cause untoward effects, an alternative built-in safety mechanism is greatly needed.  
Consequently, the development of repressible systems in VACV could provide a built-in 
safety mechanism that addresses these concerns by allowing us to repress the expression 
of VACV genes essential for viral replication.   
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2.1.  ABSTRACT 
A recombinant vaccinia virus (VACV) that contains elements from the lactose 
(lac) and the tetracycline (tet) operon systems of E. coli arranged in a gene circuit to 
conditionally control the expression of a reporter gene, enhanced green fluorescent 
protein (EGFP), was developed.  In the absence of inducers, EGFP expression in infected 
cells was detectable, but less than a positive control virus expressing the gene 
constitutively under the same promoter.  However, in the presence of increasing 
concentrations of a lac operon inducer alone (isopropyl-β-D-thiogalactoside, IPTG), 
EGFP expression increased in a dose dependent manner and at high IPTG concentrations, 
expression reached the same levels as a positive control virus.  Additionally, in the 
presence of increasing concentrations of the tet operon inducer only (doxycycline, DOX), 
EGFP expression decreased in a dose dependent manner and at high concentrations of 
DOX, expression was repressed to the degree observed in a negative control virus that 
does not express EGFP.  Thus, a dimmer-like modulation of expression can be achieved 
using different concentrations of either inducer.  Furthermore, EGFP expression was 
modulated in the presence of both inducers, much like a double rheostat circuit, and even 
after infection.  This modulatory expression system has potential applications for 
studying VACV genes in their life cycle or a means to regulate the expression of genes 
for the development of novel vaccines and cancer therapies.   
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2.2.  INTRODUCTION 
Vaccinia virus (VACV) belongs to the family Poxviridae, has a 190 kb dsDNA 
genome, and autonomously replicates in the host cell cytoplasm.   Historically, VACV 
has gained much attention.  First, it was used as a vaccine to eradicate variola virus, 
which caused smallpox disease (Fenner and World Health Organization, 1988).  After 
this great achievement, advancements in genetic engineering allowed VACV to be used 
as a viral vector and to be studied in more detail (Mackett et al., 1982, Mackett et al., 
1984, Moss, 1991, Moss, 1996). A popular technique used to study this complex virus is 
to place VACV genes under the conditional control of elements from either the 
tetracycline (tet) or the lactose (lac) operon from E. coli (Fuerst et al., 1989, Traktman et 
al., 2000), so that the role of the gene in the viral life cycle can be studied in the absence 
or presence of the respective operon inducers.  In addition, these inducible expression 
systems can have practical applications to regulate the expression of VACV or 
heterologous genes, as there is a renewed interest for using VACV as a live viral vector 
for smallpox vaccines, heterologous vaccines, and cancer therapies (Verardi et al., 2012).   
The construction of these inducer-dependent VACV recombinants entails an E. 
coli repressor gene (lacI or tetR) that is constitutively expressed by a VACV early/late 
promoter and an E. coli operator sequence (lacO or tetO) that is placed downstream from 
a VACV promoter and upstream from the start site of a VACV gene.  In the absence of 
lac operon inducers, such as isopropyl-β-D-thiogalactoside (IPTG), or tet operon inducers, 
tetracyclines (TCs) such as tetracycline (TET) or doxycycline (DOX), the transcription of 
the gene of interest is blocked and the observed phenotypes (e.g., smaller plaque 
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phenotype or no mature virion formation via electron microscopy) can be interpreted to 
yield information on the essentiality and functionality of a gene of interest.   
Although inducible systems are useful in characterizing VACV genes, only the 
induction of gene expression and the resulting phenotype can be effectively studied.  
After induction and infection, the removal of the inducer (e.g., by washing the cells with 
medium) is difficult, especially if expression at certain time points is being characterized.  
The inducer already present within the cell will not lead to full repression of gene 
expression in a timely fashion.  Thus, a new modulatory system that allows for either 
quick repression or induction of gene expression by the addition (and not removal) of 
particular inducers offers a new and efficient way of studying the role of genes in the 
viral life cycle.   
Despite the renewed interest in VACV as a replication competent vaccine and 
therapeutic vector, there is a growing subset of the population that is contraindicated 
against VACV vaccination as the infection could lead to severe adverse events, including 
death.  This population includes the immunosuppressed, cancer therapy patients, 
individuals with atopic dermatitis, and individuals with heart conditions (Kemper et al., 
2002).  Thus, an approach to increase the safety of VACV vectors is to place a gene 
essential to viral replication under the control of a repressible system, which could serve 
as a built-in safety system.  In cases where adverse events were to occur, transcription of 
a gene essential to viral replication could be blocked upon administration of an inducer, 
thus stopping the replication of the virus and most importantly, the progression of the 
adverse event. 
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In this study, elements from both the lac and the tet operons of E. coli, arranged 
via a gene circuit, were used to generate a recombinant VACV called vIRG, that is 
dependent on TCs to repress the expression of a reporter gene, enhanced green 
fluorescent protein (EGFP).  Additionally, we found that in the presence of IPTG, EGFP 
expression can be induced.  Thus, we describe a system that can modulate the EGFP 
expression much like a dimmer or double rheostats that can be controlled independently 
in the presence of appropriate inducers.   
 
2.3.  MATERIALS AND METHODS 
 
Viruses and Cell Cultures. African green monkey kidney (BS-C-1) and human (HeLa 
S3) cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% TET tested fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA) 
at 37°C in 5% CO2.  A clone derived from the Western Reserve (WR) strain of VACV 
(ATCC VR-2035) and all recombinant VACVs were propagated in BS-C-1 and HeLa S3 
cells and titered by plaque assay in BS-C-1 cells.   
 
Transfer Vectors.  The construction of the vIRG transfer vector (pAT015) is detailed in 
Figure 2.1.  Plasmid pAT009 is a designed synthetic plasmid (DNA2.0, Menlo Park, CA) 
that contains the lacI ORF, a multiple cloning site (MCS), and the late VACV P11 
promoter with a synthetic 22 bp lacO sequence (Sadler et al., 1983) located immediately 
downstream from the promoter transcriptional start site.  The restriction sites BglII and 
BspEI flank the entire construct within pAT009 and this BglII-BspEI fragment was 
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cloned into the same sites of pSMART15 (Weber et al., 2007), generating pAT014.  
pSMART15 contains tetR under the control of a strong synthetic VACV early/late 
promoter (PE/L) (Chakrabarti et al., 1997), the DsRed-Express gene under the control of 
an additional (back-to-back) VACV PE/L promoter with a 19 bp tetO2 sequence placed 
directly downstream from the late transcriptional start site, and the gpt-gus fusion gene 
under the control of a synthetic early/late VACV Psel promoter (Hammond et al., 1997), 
flanked by segments of the VACV thymidine kinase (TK) gene (left, TKL and right, TKR), 
which allow for homologous recombination with the VACV TK genomic region.  The 
final transfer vector (pAT015) was generated by transferring the EGFP gene (Thastrup et 
al., 2001) from pAT010 (DNA2.0) into the BamHI and EagI sites of pAT014.  Similarly, 
a transfer vector with EGFP under the control of P11 lacking the tetO2 sequence was also 
generated to serve as a positive control.   Additionally, transfer vectors with lacI under 
the control of PE/L with multiple operator sequences and arrangements were generated, 
with two tandem tetO2 sequences separated by 2 bp (2×tetO2(2)) or 11 bp (2×tetO2(11)), 
as well as tandem tetO1 and tetO2 operators separated by 11 bp (tetO1/O2(11)) (Yao et al., 
1998).  These transfer vectors were generated by replacing the BglII-XmaI fragment of 
pAT015 (containing the PE/L-tetO2 fragment) with the respective promoter fragments 
from plasmids pSMART16, pSMART17, and pSMART18  (Weber et al., 2007).   
 
Generation of Recombinant VACVs.  Recombinant VACVs vIRG (1×tetO2), vIRG2 
(2×tetO2(2)), vIRG3 (2×tetO2(11)), vIRG4 (tetO1/O2(11)), and vRGc (no tetO, positive 
control virus constitutively expressing EGFP) were generated via standard homologous 
recombination by transfection of the transfer vectors into BS-C-1 cell monolayers 
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infected with VACV strain WR (also used as the negative control) at a multiplicity of 
infection (MOI) of 0.05 plaque-forming units (PFU)/cell.  Recombinant VACVs were 
plaque purified in selection medium (25 µg/ml mycophenolic acid, 250 µg/ml xanthine, 
15 µg/ml hypoxanthine, in the absence or presence of 5 mM IPTG); plaques were 
visualized either with substrate 5-bromo-4-chloro-3-indolyl-β-D-glucuronide (X-Gluc) or 
by selecting and collecting only EGFP+ expressing plaques detected via fluorescence 
microscopy.  The purity of the recombinant VACVs (absence of parental virus) were 
confirmed by checking multiple dilutions of stocks in selection-free media (with 5 mM 
IPTG) for the presence of non-fluorescent (EGFP-) plaques.  High titer stocks of each 
recombinant VACV were generated by infecting HeLa S3 cells at an MOI of 0.1.  
Infected cells were harvested 3 days post-infection (DPI) by centrifugation at 200 × g for 
10 min.  Cells were then lysed by freezing and thawing, sonicated, and trypsinized.  
Finally, cell lysates were clarified to remove contaminating cell debris by a second round 
of sonication and centrifugation at 200 × g for 5 min.   
 
Determination of EGFP Expression.  BS-C-1 cell monolayers in multiwell culture 
plates were infected with vIRG, vRGc, or WR (30 PFU or an MOI of 1) in the presence 
of medium only or various concentrations of IPTG, DOX, TET, or anhydrotetracycline 
(ATC).  At 2 DPI, EGFP expression by isolated plaques or infected cells were determined 
by quantitative fluorescence microscopy (as described below).  In certain instances, cell 
monolayer, were washed with 1× phosphate-buffered saline (PBS) pH 7.2, resuspended 
in equal parts of 1× PBS and 2% neutral buffered formalin (1% final concentration), and 
analyzed with a fluorescence plate reader (as described below) within 24 hr.   
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Modulation of EGFP Expression.  BS-C-1 cell monolayers in multiwell culture plates 
were infected with vIRG, vRGc, or WR (30 PFU or an MOI of 1) in the presence of 
medium only or various concentrations of DOX and IPTG, and 2 DPI plaques were 
imaged via fluorescence microscopy.  Additionally, HeLa S3 cell monolayers were 
infected at an MOI of 1 in various concentrations of DOX or IPTG, and 24 hr later cells 
were trypsinized for 5 min on plate shaker (low setting), centrifuged 300 × g for 10 min, 
resuspended in equal parts of 1× PBS and 2% neutral buffered formalin (1% final 
concentration), and analyzed by flow cytometry within 24 hr.  Briefly, 10,000 cells were 
analyzed in a FACScan (Becton Dickinson, Rutherford, NJ) flow cytometer and the 
CellQuest software (Becton Dickinson) was used to gate cell populations based on 
forward and side scatter and to determine the mean fluorescence (488 nm excitation and 
530/30 emission).   
 
EGFP Expression Kinetics.  First, the inducibility of EGFP expression was tested by 
infecting BS-C-1 cell monolayers with vIRG, vRGc, or WR at an MOI of 1 in the 
presence of 1 mM IPTG added at the time of infection or several times post-infection.  
Cells were imaged and quantified at each time point as described below.  In addition, the 
repressibility of EGFP expression was tested by first infecting cells as above in the 
presence of 1 mM IPTG, and then adding DOX (100 ng/ml) at various time points post-
infection.   
 
  35 
Imaging and Image Quantification.  Infected cells and plaques were imaged using an 
inverted fluorescence microscope (Axio Observer D1, Carl Zeiss, Thornwood, NY) with 
or without a green bandpass filter (XF100-2, Omega Optical, Brattleboro, VT).  EGFP 
expression levels were quantified with the AxioVision software, release 4.8.1 (Carl Zeiss).   
 
Fluorescence Quantification with a Microplate Reader.  The fluorescence readings of 
infected cells were obtained with a fluorescence plate reader (Synergy HT Multi-Mode 
Microplate Reader, BioTek Instruments, Winooski, VT) using a 485/20 nm excitation 
and a 528/20 nm emission filter pair.  EGFP expression levels are quantified with the 
KC4 v3.4 software (BioTek Instruments).   
 
2.4.  RESULTS   
 
EGFP Expression Levels by vIRG in the Absence of lac and tet Operon Inducers is 
Lower than Expected.  In the absence of inducers, BS-C-1 cells infected with vIRG, a 
negative control virus (WR), or a positive control virus (vRGc) all displayed the expected 
cytopathic effect (CPE) 2 DPI and when observed under brightfield microscopy (Figure 
2.2).  Under fluorescence microscopy, vIRG infected cells displayed detectable levels of 
EGFP expression (Figure 2.2).  However, the observed EGFP expression levels were 
significantly lower than those observed for the positive control virus (vRGc) (Figure 2.2).  
This result was unexpected as we anticipated that vIRG would be completely unrepressed 
in the absence of inducers.   
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IPTG Induces Higher EGFP Expression Levels by vIRG in a Dose Response 
Manner.  A likely mechanism for the observed intermediate level of EGFP expression by 
vIRG is the leaky expression of lacI under the control of the strong early/late synthetic 
promoter PE/L.  In such case, any expressed LacI repressor would bind to the tetO2 
sequence downstream from the EGFP promoter, reducing EGFP expression.  To test this 
possibility, BS-C-1 cells were infected with vIRG in the presence of 1 or 5 mM of IPTG, 
a lac operon inducer.  Previously, concentrations of IPTG between 0.1-5 mM were used 
in a lac inducible expression system in VACV (Fuerst et al., 1989).  The CPE observed 
by brightfield microscopy 2 DPI in cells treated with 5 mM IPTG was indistinguishable 
from the CPE observed in cells that did not receive IPTG (Figure 2.3). Moreover, 
fluorescence microscopy indicated that infected cells treated with IPTG displayed 
significantly higher levels of EGFP expression levels when compared with untreated cells 
(Figure 2.3).  To quantitate the levels of EGFP expression, cells were infected at an MOI 
of 1 in the presence of 1 mM IPTG (Figure 2.4) and analyzed by quantitative 
fluorescence microscopy (Figure 2.5).  The addition of IPTG resulted in EGFP 
expression levels by vIRG that were at the same levels as vRGc.  This would be expected 
since any potential LacI repressor present (e.g., by leaky expression) should undergo a 
conformational change in the presence of IPTG so that it no longer binds onto its cognate 
lacO sequence.  Furthermore, when increasing concentrations of IPTG were added to 
cells infected with vIRG, EGFP expression levels increased in a dose dependent manner 
(Figure 2.6).  Therefore, in a system in which basal EGFP expression levels were 
intermediate, the addition of IPTG resulted in an inducible expression system.   
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DOX Completely Represses EGFP Expression by vIRG in a Dose Response Manner.  
Although we were able to demonstrate that EGFP expression was inducible, our initial 
goal was to develop a system that was able to represses EGFP expression in the presence 
of tet operon inducers.  Previously, a variety of TET derivatives have been used in tet 
systems.  For example, TET and DOX at concentrations between 0.1-1 µg/ml were 
successfully used in the inducible VACV expression systems (Traktman et al., 2000, 
Weber et al., 2007).  In addition, ATC (a TET derivative with minimal antibiotic activity) 
has been used at concentrations of 0.4 µM (185 ng/ml) in bacterial expression systems 
(Scholz et al., 2003, Scholz et al., 2004).  Thus, to determine if EGFP expression was 
repressible, DOX, TET, and ATC were added to cells infected with vIRG and expression 
of EGFP was quantified with a fluorescence microplate reader (Figure 2.7).  At 2 DPI, no 
detectable differences in CPE were observed between any TC-treated and untreated cells 
via brightfield microscopy (data not shown).  In the presence of TCs, EGFP expression 
was repressed to differing degrees depending on the type and concentration of TC used.  
The repression of EGFP expression was very sensitive to DOX, followed by ATC and 
TET.  DOX at 1 ng/ml was sufficient to repress EGFP expression to the level of the 
negative control virus, WR.  At higher concentrations of ATC, there was a small 
detectable increase in fluorescence, which was also confirmed by fluorescence 
microscopy (data not shown).  Additionally, ATC is associated with side effects such as 
cutaneous phototoxicity and Fanconi-type syndrome in humans (Burgos et al., 2011).  
Therefore, DOX was used for further characterization, as it is the most sensitive in 
repressing EGFP expression, it does not exhibit a high degree of autofluorescence, and is 
an FDA approved drug.   
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To demonstrate that EGFP expression levels can be repressed to fluorescence 
levels compared to WR, cells were infected with WR or vIRG in the absence or presence 
of 100 ng/ml of DOX (Figure 2.8).  In the absence of DOX, EGFP expression (measured 
in arbitrary fluorescence units) by vIRG was higher than in WR-infected cells.  In the 
presence of DOX, EGFP expression by vIRG was repressed to the same level as WR.  
WR fluorescence levels stayed the same in the absence or presence of DOX.  Finally, as 
increasing concentrations of DOX were added to cells infected with vIRG, EGFP 
expression levels decreased in a dose dependent manner and at 10 ng/ml, EGFP 
expression was repressed to levels comparable to WR (Figure 2.9).  Thus, we were able 
to show that this novel VACV expression system has the ability to display both inducible 
and repressible gene expression phenotypes in the presence of the appropriate inducers.   
 
Rheostat Modulation of EGFP Expression.  The inducible and repressible capabilities 
of vIRG allow the modulation of EGFP expression in a dimmer-like fashion, using the 
appropriate inducers.  To demonstrate the range of EGFP expression in this system, cells 
were infected with vIRG in the absence or presence of increasing concentrations of DOX 
or IPTG.  As observed initially, cells infected with vIRG in the absence of inducers 
(media only) yielded intermediate levels of EGFP expression (Figure 2.10).  EGFP 
expression could be repressed by treating with increasing concentrations of DOX, or 
could be induced by adding increasing concentrations of IPTG.   
Flow cytometry (a more sensitive tool to detect EGFP expression) was also used 
to quantify the range of gene expression that can be achieved with vIRG.  In a 
preliminary study, HeLa S3 cells were infected with vIRG, WR or vRGc in the absence 
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or presence of varying concentrations DOX or IPTG (Figure 2.11).  vIRG exhibited the 
same trends of repression and induction as observed by fluorescence microscopy and 
microplate reader.  However, EGFP expression did not seem to be fully repressed to WR 
levels or induced to the same levels of vRGc.  These results could be due to a variety of 
factors such the use of a different cell line, small number of cells analyzed, acquisition or 
analysis settings (such as the gating of infected cells, since at an MOI of 1 only about 
63% of the cells are expected to be infected), and the fact that control virus measurements 
were taken in the absence of inducers.  Nonetheless, both methods show that EGFP 
expression by vIRG could be modulated in the presence of increasing concentrations of 
DOX or IPTG.   
Next, we tested the system in BS-C-1 cells infected with vIRG in the presence of 
varying concentrations of both DOX and IPTG (Figure 2.12).  EGFP expression in these 
conditions followed the same trends of induction in the presence of increasing 
concentrations of IPTG and repression in the presence of increasing concentrations of 
DOX.  Furthermore, in the presence of the highest concentration of DOX (where EGFP 
expression is similar to the level of the negative controls virus), the addition of increasing 
concentrations of IPTG to the induction of EGFP expression, without the removal of 
DOX.  Conversely, in the presence of the highest concentration of IPTG (that induces 
EGFP expression to maximal levels), the addition of DOX leads to the repression of 
EGFP expression.  Thus, the vIRG system also allows a double rheostat-like modulation 
of gene expression, so that two independent “switches” (inducers) can be used to 
simultaneously modulate EGFP expression.   
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Kinetics of EGFP Induction by vIRG.  To study the kinetics of EGFP expression by 
vIRG, BS-C-1- cells were infected with vIRG, WR, or vRGc and treated with IPTG (1 
mM) at various time points post-infection and EGFP expression was quantified at every 
time point (Figure 2.13).  The different IPTG treatments did not alter the EGFP 
expression kinetics for WR and vRGc.  As observed initally, in the absence of IPTG, 
vIRG expressed intermediate levels of EGFP (fluorescence measurements are higher than 
WR).  EGFP expression by vIRG treated with IPTG at 0, 3 and 12 hr did not differ 
significantly and peaked at 48 hr post-infection (similar to vRGc).  This is most likely 
due to the late promoter (P11) that drives EGFP expression in this system.  Conversely, 
EGFP expression by vIRG increased dramatically after the addition of IPTG between 18 
and 48 hr post-infection.  Thus, induction of this system can be tightly regulated even 
after infection.   
 
 
Kinetics of EGFP Repression by vIRG.  To study the kinetics of repression of EGFP 
expression, BS-C-1 cells were infected with vIRG in the presence of 1 mM IPTG (to 
induce expression) and then treated with DOX (100 ng/ml) at several time points post-
infection (to repress expression) (Figure 2.14).  As observed initially, vIRG grown in 
medium only had measurable levels of  EGFP expression (fluorescence higher than WR).  
In the presence of IPTG only, vIRG expressed levels of EGFP comparable to the positive 
control virus (vRGc).  In the presence of IPTG, addition of DOX between 0-12 hr post-
infection produced expression curves that were similar to vIRG grown in the absence of 
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DOX.  Thus, DOX treatment between 0 and12 hr post-infection halts the expression of 
EGFP.  Again, this is likely due to the late P11 promoter that drives expression of EGFP 
to high levels only after 12 hr post-infection, as observed in vRGc.  Conversely, cells 
infected with vIRG in the presence of IPTG and treated with DOX at 18 and 24 hr 
displayed a significant increase in EGFP expression before DOX exposure; however, 
EGFP expression was repressed and eventually plateaued after DOX exposure.  Thus, 
repression in this VACV gene expression system can be tightly regulated even after 
infection.   
 
Addition of tetO Operators in Different Numbers and Arrangements Does Not 
Prevent Leaky Expression of LacI.  A number of recombinant VACVs derived from 
vIRG were developed with the lacI gene under the control of the PE/L promoter with 
multiple tetO operator sequences and arrangements: two tandem tetO2 sequences 
separated by 2 bp (2×tetO2(2), vIRG2) or 11 bp (2×tetO2(11), vIRG3), as well as tandem 
tetO1 and tetO2 operators separated by 11 bp (tetO1/O2(11), vIRG4), as described by 
Weber et al. (Weber et al., 2007).  BS-C-1 cells were infected with the different viruses in 
the absence or presence of 5 mM IPTG, and isolated plaques were imaged by 
fluorescence microscopy (Figure 2.15).  The levels of EGFP expression in the absence of 
IPTG do not differ between the different recombinant VACVs, indicating that the 
different number and arrangements of tetO operators tested were not able to stop leaky 
expression of LacI.   
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2.5.  DISCUSSION AND CONCLUSIONS   
We developed a gene modulation system in VACV that is not only repressible, 
but also inducible in the presence of the appropriate inducers.  However, it was not our 
initial expectation that vIRG would also result in an inducible system as the development 
of this project initially focused on the design of a repressible system.  The vIRG 
expression system is able to exhibit both inducible and repressible capabilities likely due 
to the unexpected leaky expression of lacI.  Therefore, in an attempt to control lacI leaky 
expression, new transfer vectors were designed with the addition of tandem tetO operator 
sequences (in different arrangements) placed downstream from the PE/L promoter 
controlling lacI expression.  However, preliminary studies indicate that this strategy does 
not seem to lower the leaky expression of lacI significantly.  This is likely because 
repression of early VACV promoters using repressor proteins such as LacI and TetR does 
not seem to be achievable using this technology, as evidenced by recent unpublished data 
from the Verardi Lab (Weber, Verardi et al, unpublished data).  Thus, an alternative 
method to control this potential leaky expression of lacI is to change the current lacI 
promoter (the early/late PE/L promoter) to the late P11 promoter, which has been 
successfully used to tightly control gene expression in VACV (C. Hagen, unpublished 
data).   
Based on this theory, we can outline a potential gene circuit mechanism 
underlying the control of gene expression in vIRG.  The constitutive expression of tetR 
should provide a continuous supply of the TetR repressor protein (Figure 2.16).  In the 
absence of inducers, there is probably an expression timing issue that leads to 
intermediate levels of EGFP expression.  We know that early transcription occurs soon 
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after infection (virus entry).  If tetR and lacI are under the control of the same strong PE/L 
promoter, then both lacI and tetR expression will ensue at rates that are initially the same.  
Thus, immediately after infection, lacI is being expressed, albeit at low levels.  As the 
TetR protein accumulates, then it can finally bind to tetO operator sequences to halt 
further transcription of lacI.  However, since the reporter gene (EGFP) is under a late 
promoter, any LacI already present in the cell will interfere with its expression, and hence 
the intermediate levels of expression.   
In conclusion, we have demonstrated a novel modulatory expression system in 
VACV that is sensitive to both the lac and the tet operon inducers, is inducible as well as 
repressible, is dose-dependent, and allows temporal regulation of gene expression even 
after infection and without the removal of the previous inducer.  This novel expression 
system has an array of potential applications in basic virology (e.g., the study of VACV 
genes and their function or temporal essentiality) and translational animal and human 
medicine (e.g., safer vaccines and therapeutic viral vectors).  One application would be to 
regulate a VACV gene of interest using this system and determine the amount and timing 
of expression necessary to allow morphogenesis and replication, so that DOX and IPTG 
could be used like independent rheostats controlling gene expression.  In another 
application, a gene that is known to be essential for viral replication could be placed 
under the control of this system to serve as a potential safety mechanism for VACV 
vectors used for vaccination or cancer therapy.  If VACV-associated complications were 
to arise, DOX administration would lead to the repression of the gene, stopping viral 
replication and halting the adverse event.   
  
2.6.  FIGURES 
FIGURE 2.1.  Construction of 
vIRG.  The cloning steps leading to the generation of the final transfer vector are shown.  
pAT015 contains the gpt-
promoter (PSel), the EGFP 
lacO sequence located directly downstream, the 
constitutive strong early/late promoter (
additional (back-to-back) P
downstream, all flanked by TK
TK gene of VACV.   
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the transfer vector pAT015 for the generation of 
gus fusion gene under the control of an early/late 
gene under the control of an engineered P11 promoter with a 
tetR gene under the control of 
PE/L), and the lacI gene under the control of an 
E/L promoter with a tetO2 sequence located directly 






FIGURE 2.2.  EGFP expression l
BS-C-1 cells infected with WR, vIRG, or vRGc in the absence of inducers displayed 
typical CPE 2 DPI, and single isolated plaques were imaged by brightfield 
fluorescence microscopy.  vIRG
levels when compared to v
fluorescence levels when compared to 
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FIGURE 2.3.  Cells infected with vIRG in the presence of 1 mM 
higher levels of EGFP.  
or presence (+ IPTG) of 5
similar CPE and single isolated plaques were imaged by brightfield 
microscopy.  Cells infected with vIRG in the presence of IPTG displayed high levels of 
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FIGURE 2.4.  EGFP expression levels in vIRG
high.  BS-C-1 cells were 
absence (- IPTG) or presence (+ IPTG) of 1 mM IPTG, and 
fluorescence microscopy.  The EGFP expression levels 
treated with IPTG were higher than in the absence of IPTG.  
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FIGURE 2.5.  Quantification of EGFP expression in BS
vIRG in the absence or 
with WR, vRGc, or vIRG 
and 2 DPI cells were imaged by f
quantified.  The EGFP expression levels 
treated with IPTG were indistinguishable and 
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FIGURE 2.6.  IPTG induces EGFP expression by vIRG in a dose 
BS-C-1 cells were infected at an MOI of 1 with WR, vIRG, or vRGc in the ab
presence of increasing concentrations of IPTG
fluorescence microscopy and EGFP expression was quantified
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FIGURE 2.7.  EGFP expression by vIRG is repressible by TCs
infected at an MOI of 1 with vIRG 
concentrations of TET, DOX
microplate reader.  EGFP expression levels were repressed in the presence of all TCs, 
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, or ATC, and 2 DPI EGFP expression was quantified with a 
Error bars are SEM, n=2.
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FIGURE 2.8.  EGFP expression by 
DOX.  BS-C-1 cells were 
DOX) or presence (+ DOX)
fluorescence microscopy and EGFP expression was quantified
vIRG in the presence of DOX was repressed to




vIRG is completely repressed in the presence of 
infected at an MOI of 1 with WR or vIRG in the absence (
 of 100 ng/ml DOX, and 2 DPI cells were imaged by 
.  EGFP expression by 










FIGURE 2.9.  Repressible dose response to increasing concentrations of 
C-1 cells were infected at an MOI of 1 with WR or vIRG in the absence or presence of 
increasing concentrations of




 DOX, and 2 DPI cells were imaged by fluorescence 









FIGURE 2.10.  Dimmer
by fluorescence microscopy
the absence or presence of varying concentrations of 
imaged by fluorescence microscopy
comparable to a negative control virus (WR) in the 




-like modulation of EGFP expression in vIRG as determined 
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FIGURE 2.12.  Double rheostat
DOX.  BS-C-1 cells were 
concentrations of DOX or IPTG
microscopy.  The resulting single plaques display a wide range of EGFP expression 
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eously modulate EGFP expression.  
 
 






FIGURE 2.13.  Kinetics of EGFP induction by vIRG
an MOI of 1 with vIRG, WR, or vRGc
shown (+ IPTG) or left untreated.  At various time 
fluorescence microscopy and EGFP expression was quantified
WR- and vRGc-infected cells were not altered by addition of IPTG (data shown are only 
in the absence of IPTG).  EGFP expression by vIRG was not 
added between 0 and 12 hr, but increased significantly when IPTG was added between 18 
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FIGURE 2.14.  Kinetics of EGFP repression by vIRG
an MOI of 1 with vIRG, WR, or vRGc
labeled medium only) and at the time points shown 
(+ DOX).  At various time points
EGFP expression was quantified
were not altered by addition of DOX (data shown are in the presence of medium only).  
EGFP expression by vIRG was not affected when DOX was added between 0 and 12
but decreased significantly when DOX
that repression can be regulated even after infection.  
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.  BS-C-1 cells were infected at 
 in the presence of 1 mM IPTG (except when 
DOX was added to 100 ng/ml
 cells were imaged by fluorescence micro
.  Fluorescence levels in WR- and vRGc









FIGURE 2.15.  Addition of 
does not seem to prevent leaky expression of LacI
the different viruses in the absence (
isolated plaques were imaged by fluorescence microscopy.  The levels of EGFP 
expression in the absence of IPTG did not differ between the different recombinant 
VACVs, indicating that the number and arrangement of 
able to stop leaky expression of LacI.  
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tetO operators in different numbers and arrangements
.  BS-C-1 cells were 
- IPTG) or presence (+ IPTG) of 5 mM IPTG, and 






FIGURE 2.16.  Schematic of the “gene circuit” 
gene expression in vIRG. 
supply of the TetR repressor protein
expressed at low levels and i
TCs (top panel), lacI is expressed abundantly, repressing the expression of EGFP.  In the 
presence of IPTG (lower panel), LacI is unable to block EGFP transcription.  
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3.1.  ABSTRACT   
A number of recombinant vaccinia viruses (VACVs) that contain elements from 
the tetracycline (tet) operon system of E. coli were developed to repress the expression of 
a reporter gene, enhanced green fluorescent protein (EGFP), in the presence of tet operon 
inducers.  The recombinant VACVs constitutively expressed six mutant versions of the 
tet repressor gene (tetR) shown to bind tet operators in the presence, but not absence of 
inducers (reverse tetR genes).  In the absence of tetracyclines (TCs), such as tetracycline 
(TET), doxycycline (DOX), and anhydrotetracyline (ATC), EGFP was expressed under 
the control of a VACV promoter containing a tet operator, albeit at different levels.  In 
the presence of TCs, all recombinants exhibited various degrees of repression of EGFP 
expression, with increasing concentrations of TCs leading to EGFP repression in a dose 
dependent manner.  All recombinants were primarily responsive to DOX, followed by 
ATC and TET.  In the presence of DOX, EGFP expression levels were similar to a 
negative control virus at concentrations as low as 10 ng/ml.  In light of the renewed 
interest for the use of VACV as vaccine and therapeutic cancer vectors, the repressible 
VACV expression system developed here can be used to tightly regulate genes essential 
for VACV replication, thus functioning as a built-in safety mechanism to conditionally 
control viral replication.   
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3.2.  INTRODUCTION 
Vaccinia virus (VACV) belongs to the family Poxviridae and has many unique 
characteristics that have led to its widespread use as a vaccine and therapeutic vector 
(Moss, 1991, Moss, 1996).  In addition to its large size (200 nm × 250 nm), VACV has a 
190 kb genome that encodes its own necessary transcription machinery and allows 
transcription to occur completely within the host cell cytoplasm.  As a viral vector,  
VACV can carry at least 25 kb of heterologous DNA (Smith and Moss, 1983), and it can 
elicit strong humoral and cell-mediated immune responses (Mackett et al., 1982).  VACV 
has become most notable for its use as the smallpox vaccine that eradicated smallpox 
worldwide (Fenner et al., 1988, World Health Organization. Global Commission for the 
Certification of Smallpox Eradication and World Health Organization, 1980).  After this 
great achievement, VACV became one of the most characterized viruses, allowing the 
development of heterologous vaccines and cancer therapeutics.   
The use of VACV as a replication competent virus is associated with severe 
adverse events, and there is a growing segment of the population for which its use is 
contraindicated (Cono et al., 2003, Lane and Goldstein, 2003).  Those that are 
immunosuppressed, have (or had) atopic dermatitis and other skin conditions, and those 
with heart conditions fall within the contraindicated population.  This is a significant 
limitation and is problematic for various reasons.  Amidst the fears of bioterrorism and 
the re-emergence of variola virus or related pathogenic poxviruses (Dhawan et al., 2001, 
Di Giulio and Eckburg, 2004, Nalca et al., 2005, Gottschalk and Preiser, 2005), the US 
has established a stockpile of the smallpox vaccine (Monath et al., 2004, Greenberg et al., 
2005, Greenberg and Kennedy, 2008).  The currently stockpiled vaccine (ACAM2000), 
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passaged in cell culture, has improved sterility (Greenberg and Kennedy, 2008, Monath 
et al., 2004) over the previously used smallpox vaccine (Dryvax), produced in the skin of 
calves (Rotz et al., 2001).  However, the adverse events associated with virus replication 
are still a significant concern with ACAM2000.  One way to address these safety 
concerns is to develop replication incompetent VACVs, such as MVA (Modified 
Vaccinia Ankara).  MVA-BN or IMVAMUNE is a potential next-generation smallpox 
vaccine that is currently on fast-track clinical trials (Kennedy and Greenberg, 2009).  
However, MVA elicits lower immune responses after a single immunization (thus 
requiring multiple doses to elicit immune responses comparable to Dryvax or 
ACAM2000) and it is replication-defective, thus unable to produce the “take”, the only 
known correlate of protection against smallpox.   
Thus, there is a need for alternative approaches to increase the safety of VACV 
while maintaining its immunogenicity and its ability to produce a take.  One approach 
that meets these criteria is to place a gene essential to viral replication under the control 
of a repressible system, which could serve as a built-in safety system.  In cases where 
adverse events were to occur, transcription of a gene essential for viral replication could 
be blocked upon administration of an inducer, thus stopping the replication of the virus 
and most importantly, the progression of the adverse event.   
In this study, elements from the tet operon of E. coli and reverse mutants of the 
tetR (revtetR) gene were used to generate recombinant VACVs that repress the 
expression of a reporter gene, enhanced green fluorescent protein (EGFP), in the presence 
of tetracyclines (TCs).   
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3.3.  MATERIALS AND METHODS 
 
Viruses and Cell Culture.  African green monkey kidney (BS-C-1) and human (HeLa 
S3) cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% TET tested fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA) 
at 37°C in 5% CO2.  A clone derived from the Western Reserve (WR) strain of VACV 
(ATCC VR-2035) and all recombinant VACVs were propagated in BS-C-1 and HeLa S3 
cells and titered by plaque assay in BS-C-1 cells.   
 
Transfer Vectors.  The construction of the vRG0 transfer vector is detailed in Figure 3.1.  
Briefly, the NheI and XmaI fragment of pAT008, a designed synthetic plasmid (DNA2.0, 
Menlo Park, CA) that contains the revtetR (L17G) gene (Scholz et al., 2004), was 
subcloned into the same sites of pSMART11 (Weber et al., 2007).  The resulting plasmid 
(pAT013) contains the revtetR gene under the control of the synthetic early/late VACV 
PE/L promoter, the DsRed gene under the control of the natural late VACV P11 promoter 
(back-to-back with the PE/L) with a 19 bp tetO2 placed directly downstream from P11 and 
upstream from the transcriptional start site, and the gpt-gus fusion gene under the control 
of the synthetic VACV PSel promoter (Hammond et al., 1997), flanked by segments of the 
VACV thymidine kinase (TK) gene (left, TKL and right, TKR), which allows for 
homologous recombination with the VACV TK genomic region.  The final transfer 
vector pAT020 was generated by transferring the EGFP gene from pAT010 into the BglII 
and BspEI sites of pAT013.  A control transfer vector (pAT018) for the generation of a 
recombinant VACV constitutively expressing EGFP under the P11 promoter (vRGc) was 
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generated by transferring the revtetR gene into plasmid pSMART10 (Weber et al., 2007), 
and by replacing the DsRed gene with the EGFP gene as described above.  Additionally, 
transfer vectors with different mutants of the revtetR gene (Table 3.1) were generated by 
subcloning the mutant revtetR synthetic genes (DNA2.0) into the NheI and XmaI sites in 
pAT020.   
 
Generation of Recombinant VACVs.  The recombinant VACVs vRG0, vRG1, vRG2, 
vRG3, vRG4, vRG5 (Table 3.1), and vRGc (a positive control virus without tetO2, thus 
constitutively expressing EGFP under the P11 promoter) were generated via standard 
homologous recombination by transfection of the transfer vectors into BS-C-1 cell 
monolayers infected with VACV strain WR (also used as the negative control) at a 
multiplicity of infection (MOI) of 0.05 plaque-forming units (PFU)/cell.  Recombinant 
VACVs were plaque purified in selection medium (25 µg/ml mycophenolic acid, 250 
µg/ml xanthine, 15 µg/ml hypoxanthine); plaques were visualized either with substrate 5-
bromo-4-chloro-3-indolyl-β-D-glucuronide (X-Gluc) or by selecting and collecting only 
EGFP+ expressing plaques detected via fluorescence microscopy.  The purity of the 
recombinant VACVs (absence of parental virus) was confirmed by checking multiple 
dilutions of stocks in selection-free media for the presence of non-fluorescent (EGFP-) 
plaques.  High titer stocks of each recombinant VACV were generated by infecting HeLa 
S3 cells at an MOI of 0.1.  Infected cells were harvested 3 days post-infection (DPI) by 
centrifugation at 200 × g for 10 min.  Cells were then lysed by freezing and thawing, 
sonicated, and trypsinized.  Finally, cell lysates were clarified to remove contaminating 
cell debris by a second round of sonication and centrifugation at 200 × g for 5 min.   
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Determination of EGFP Expression.  BS-C-1 cell monolayers in multiwell culture 
plates were infected with the VACVs (30 PFU or an MOI of 1) in the presence of 
medium only or various concentrations of anhydrotetracycline (ATC; with or without 
various concentrations of MgCl2, allowed to form a complex for 1 hr before use), 
tetracycline (TET), or doxycycline (DOX).  At 2 DPI, EGFP expression by isolated 
plaques or infected cells were determined by quantitative fluorescence microscopy (as 
described below).  In certain instances, cell monolayers were washed with 1× phosphate-
buffered saline (PBS) pH 7.2, resuspended in equal parts of 1× PBS and 2% neutral 
buffered formalin (1% final concentration), and analyzed with a fluorescence plate reader 
(as described below) within 24 hr.   
 
Imaging and Image Quantification.  Infected cells and plaques were imaged using an 
inverted fluorescence microscope (Axio Observer D1, Carl Zeiss, Thornwood, NY) with 
or without a green bandpass filter (XF100-2, Omega Optical, Brattleboro, VT).  EGFP 
expression levels were quantified with the AxioVision software, release 4.8.1 (Carl Zeiss).   
 
Fluorescence Quantification with a Microplate Reader.  The fluorescence readings of 
infected cells were obtained with a fluorescence plate reader (Synergy HT Multi-Mode 
Microplate Reader, BioTek Instruments, Winooski, VT) using a 485/20 nm excitation 
and a 528/20 nm emission filter pair.  EGFP expression levels are quantified with the 
KC4 v3.4 software (BioTek Instruments).   
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3.4.  RESULTS   
 
vRG0 Expresses EGFP at High Levels in the Absence of TCs.  The first mutant 
revtetR tested in this system was based on a tetR mutant with a single amino acid change 
at position 17 that changes leucine to glycine (L17G) (Scholz et al., 2004).  Although this 
L17G revTetR mutant was characterized in bacteria (E. coli), it was appealing to test 
initially in this system, since a single mutation is less likely to alter other important 
regions on the repressor protein. In addition, this mutant was characterized as a single 
domain protein, unlike most other revtetR mutants that were characterized as fusion 
proteins with the VP16 transcriptional activator from herpes simplex virus.  Moreover, it 
is important to note that ATC (a TC-derivative) was used to characterize the L17G 
mutant in E. coli.   
In the absence of TCs, BS-C-1 cells infected with vRG0, a positive control virus 
(vRGc) or a negative control virus (WR) displayed the expected cytopathic effect (CPE) 
2 DPI when observed under brightfield microscopy.  Additionally, vRG0 and vRGc 
plaques displayed similar high levels of EGFP expression under fluorescence microscopy, 
while WR-infected cells did not (Figure 3.2).   
 
EGFP Expression Levels by vRG0 were not Repressed even in the Presence of High 
Concentrations of TCs.  To test whether vRG0 was repressible by TCs, BS-C-1 cells 
were infected with vRG0 in the presence of increasing concentrations of ATC, TET, or 
DOX.  The CPE observed by brightfield microscopy 2 DPI was indistinguishable from 
the CPE observed from cells treated with ATC and 10 µg/ml or less of TET or DOX 
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(Figure 3.3).  However, cells infected in the presence of 100 µg/ml of TET or DOX 
exhibited morphology associated with cell toxicity, and as a result the plaques were 
smaller in comparison to infected cells treated with lower concentrations of TET or DOX.  
Cells infected in the presence of ATC did not incur any toxicity because lower 
concentrations were used in comparison to the TET and DOX, as ATC has the highest 
affinity for revTetR (Scholz et al., 2004).  Increasing concentrations of TCs did not 
decrease EGFP expression in vRG0 plaques when observed by fluorescence microscopy.  
In the presence of 100 µg/ml of TET or DOX, infected cells exhibited lower EGFP 
expression, probably due to cell toxicity.   
Since TCs complexed to MgCl2 bind to the TetR repressor with higher affinity 
than TCs alone (a commonly used strategy when studying induced conformation of the 
repressor by x-ray crystallography), we decided to incubate ATC with MgCl2 to allow for 
complex formation (Kamionka et al., 2004, Scholz et al., 2003).  Cells infected with 
vRG0 in the presence of varying concentrations of ATC-MgCl2 displayed typical CPE 2 
DPI at 20 mM or below of MgCl2, while at the highest concentration of MgCl2 (100 mM 
MgCl2), the cells exhibited toxicity-associated morphology (data not shown).  When 
plaques were observed by fluorescence microscopy, there was no EGFP repression in the 
presence of increasing concentrations of the ATC-MgCl2 complex (Figure 3.4).  In 
addition, at the highest concentrations of ATC-MgCl2 complex tested (100 mM), no 
fluorescent plaques were observed, probably as a result of MgCl2 cell toxicity.  Thus, we 
concluded that that vRG0 was not repressible and decided to test new revtetR mutants 
(Table 3.1).   
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RevTetR mutants Lead to Different EGFP Expression Levels in the Absence of TCs.  
Five new recombinant VACVs (vRG1, vRG2, vRG3, vRG4, and vRG5) were generated 
(Table 3.1), each expressing a different mutant tetR gene previously shown to display the 
reverse phenotype in eukaryotic systems when fused to a VP16 domain from herpes 
simplex virus that induces gene expression.  Since the transactivator will not function in 
VACV, as VACV relies on its own specialized transcription machinery, we tested the 
revTetR mutants without the VP16 transactivator.  Additionally, these mutants were 
initially characterized with the TC derivative, DOX; TET and DOX between 0.1 to 1 
µg/ml was successfully used in TC-inducible VACV expression systems (Trakman et al., 
2000, Weber et al. 2007).  Furthermore, DOX is an FDA approved, broad-spectrum drug 
that exhibits antimicrobial and off target activities (Greenwald et al., 2001)   
In the absence of TCs, BS-C-1 cells infected with the VACVs displayed the 
expected CPE 2 DPI under brightfield microscopy.  When observed under fluorescence 
microscopy, vRG5, vRG0, and vRGc plaques displayed similar high levels of EGFP 
expression (Figure 3.5).  The other recombinants had varying lower levels of expression, 
with vRG3 and vRG4 having equal levels of EGFP expression, vRG2 less, and vRG1 
least.   
 
RevTetR mutants Lead to Different Repression of EGFP Expression Levels in the 
Presence of TCs.  BS-C-1 cells were infected with the different VACVs at an MOI of 1 
in the absence or presence of varying concentrations of TCs.  Two DPI cells were imaged 
by brightfield and fluorescence microscopy and EGFP expression was subsequently 
quantified.  Based on fluorescence microscopy images (Figure 3.6) and quantification 
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(Figures 3.7, 3.8, and 3.9), all revTetR mutants displayed varying levels of EGFP 
repression, generally being most sensitive to DOX, followed by ATC and then TET.  
vRG0 was repressible, but EGFP expression remained high even at the highest 
concentrations of TCs tested.  In the presence of DOX, only vRG1 and vRG2 fully 
repressed EGFP expression to the levels of the negative control WR at 0.1 µg/ml, 
although EGFP expression levels by vRG1 in the absence of TCs were the lowest (Figure 
3.9).  In addition, vRG4 was able to be fully repressed at 1 µg/ml of DOX, while vRG3 
was fully repressed at 10 µg/ml of DOX.  In the absence of TCs, vRG5 was able to 
express EGFP at the same level as vRGc, although it was not able to become fully 
repressed based on fluorescence imaging quantification.   
 
Fluorescence Multiwell Reader Displays Higher Sensitivity at Low Levels of EGFP 
Expression.  To potentially increase the sensitivity and reproducibility of the 
fluorescence quantification and to better ascertain the repressible systems that exhibit full 
repression, a fluorescence plate reader (fluorometer) was employed.   BS-C-1 cells were 
infected with the VACVs at an MOI of 1 in multiwell plates in the absence or presence of 
increasing concentrations of TCs, and 2 DPI cells were fixed and read on the multiwell 
fluorescence reader (Figure 3.10, 3.11, and 3.12).  The results follow essentially the same 
trends observed by fluorescence imaging.  In addition, it seems that lower levels of EGFP 
expression were detected with increased sensitivity, although there was more variance at 
higher levels of EGFP expression.  Thus, for the purposes of determining EGFP 
repression by the recombinant VACVs, the fluorometer seems more appropriate as it is 
more sensitive at lower levels of expression.   
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Full Repression of EGFP Expression is Achievable in VACV.  To determine the TC 
concentration that fully represses EGFP expression, BS-C-1 cells were infected with the 
VACVs in the absence or presence of increasing concentrations of TCs, and 2 DPI cells 
were fixed and read on the fluorescence multiwell reader.  In the presence of increasing 
concentrations of ATC (0.1 ng/ml – 1,000 ng/ml), vRG1-vRG5 showed a repressible 
dose response (Figure 3.13).  vRG1 was fully repressed to the levels of the negative 
control WR in the presence of 100 ng/ml ATC, while vRG2, vRG3, and vRG4 were fully 
repressed in the presence of 1,000 ng/ml ATC.  Only vRG5 and vRG0 were not fully 
repressed at 1,000 ng/ml of ATC.   
In the presence of increasing concentrations of TET (1 ng/ml – 10,000 ng/ml), the 
expression in vRG1-vRG5 also showed a repressible dose response (Fig. 3.14).  However, 
vRG1 was the only recombinant that became fully repressed to the levels of WR.  In the 
presence of increasing concentrations of DOX (1 ng/ml – 10,000 ng/ml), all recombinant 
VACVs show a repressible dose response (Figure 3.15).  With the exception of vRG0 and 
vRG5, all other recombinants were fully repressed by concentrations of DOX within the 
range tested; however, some recombinant VACVs are more sensitive to DOX than others.  
vRG1 was fully repressed at 10 ng/ml of DOX, vRG2 was next at 100 ng/ml, and vRG3 
and vRG4 were next at 1,000 ng/ml.  At the highest DOX concentration tested (10,000 
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3.5.  DISCUSSION AND CONCLUSIONS 
All of the revTetR repressor mutants tested in this VACV expression system 
displayed a repressible phenotype in the presence of TCs, albeit with unique phenotypes.  
For example, vRG0 (with the single L17G tetR mutant) was only marginally repressible, 
while the recombinant VACV most sensitive to TCs (vRG1) was also the one with the 
lowest level of EGFP expression in the absence of TCs.  As a general trend, the higher 
the level of EGFP expression in the absence of TCs, the higher the TC concentration 
needed to completely repress the system.   
An aspect that can be tested with this repressible system is whether EGFP 
expression can be repressed even after infection.  As it was demonstrated in Chapter 2 in 
a modulatory expression system that is both repressible and inducible, EGFP expression 
could be stopped in the presence of DOX at various time points post-infection (Titong 
and Verardi, unpublished data).  Similar experiments could demonstrate if this is true in 
this revTetR based repression system.   
Another interesting aspect of this work is the sensitivity of fluorescence 
quantification.  In this repressible system, the main goal is to establish levels of 
repression, in particular how close EGFP expression levels are to negative control levels.  
The use of quantitative fluorescence imaging was reliable for the measurement of high 
fluorescence levels, but the multiwell fluorometer was considerably more sensitive for 
measurements of low levels of fluorescence, despite having greater variation in the higher 
ranges of expression.   
There are many applications for which the different revTetR versions in these 
repressible systems can be used.  In some cases, genes may not necessarily have to be 
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expressed at high levels to achieve the necessary phenotype.  In general, enzymes are an 
example of a class of genes do not need high levels of expression, in which case the 
vRG1 or vRG2 systems could be appropriate to use.  In other cases, such as for the 
expression of virion structural proteins, higher levels of expression may be needed and 
vRG3, vRG4, or vRG5 may be more applicable as each exhibits increasing levels of 
expression in the absence of TCs.   
Increasing the safety profile of VACV vectors can be used for the development of 
the next-generation smallpox vaccines, human and animal VACV-vectored vaccines, as 
well as immune and oncolytic therapies.   More specifically, a new generation of 
smallpox vaccine can be generated by placing a gene essential for viral replication under 
the control of a repressible system.  This next-generation smallpox vaccine would not be 
inferior to previous vaccines as it would replicate in the absence of TCs and it would be 
functionally identical to Dryvax or ACAM2000 and produce the only established 
correlate of protection (the take).  Importantly, this new vaccine would have an enhanced 
safety profile as this built-in safety mechanism could stop viral replication after 
administration of FDA approved TCs (such as DOX) in the event of adverse reactions to 
vaccination.   
Another example in which a repressible system would be extremely useful is the 
current Raboral V-RG (Merial, Duluth, GA) sylvatic rabies vaccine, a VACV-vectored 
vaccine expressing the glycoprotein of rabies that is widely used to control sylvatic rabies 
(Pastoret and Brochier, 1996, Brochier et al., 1996).  The means in which this vaccine is 
delivered poses great risks, especially to those with contraindications against vaccination 
with VACV.  Vaccine baits are dropped in wooded areas, in some cases these areas are 
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very near urbanized settings (Reynolds et al., 2007).  Thus, humans have the potential to 
be exposed to the live vaccine (Centers for Disease Control and Prevention (CDC), 2009).  
By using our built-in safety repressible mechanism, a newer generation of recombinant 
rabies vaccines could be developed.  Should a contraindicated individual accidentally 
come into contact with vaccine baits, any adverse events due to VACV infection could be 
stopped with the administration of TCs.   
VACV on its own has an array of practical applications and has led to great 
achievements in medicine.  We have successfully described an unique repressible system 
that can be built into VACV and used to greatly improve its safety profile as a viral 
vector for vaccines and immunotherapeutics.   
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FIGURE 3.1.  Construction of the transfer vector pAT015 for the generation of 
vRG0.  The cloning steps leading to the generation of the final transfer vector are shown.  
pAT020 contains the gpt-gus fusion gene under the control of a synthetic early/late 
VACV promoter (PSel), the EGFP gene under the control of an engineered late P11 
promoter with a  tetO2 sequence located directly downstream, the revtetR gene under the 
control of a constitutive strong synthetic early/late promoter (PE/L), all flanked by TKL 
and TKR sequences that direct recombination with the TK gene of VACV.   
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FIGURE 3.2.  vRG0 expresses EGFP at high levels in the absence of TCs
cells infected with WR, vRGc, or vRG0 in the absence of TCs displayed typical CPE 2 
DPI, and single isolated plaques were imaged by brightfield and fluorescence microscopy.  
Plaques from vRG0 and vRGc (positive control virus) displayed similar hig
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FIGURE 3.3.  EGFP expression levels by vRG0 were not repressed in the presence 
of TCs.  BS-C-1 cells infected with vRG0 in the presence of TCs displayed typical CPE 
2 DPI in all concentrations of ATC or 10 µg/ml or less of TET or DOX.  However, cells 
infected with 100 µg/ml of TET or DOX exhibited morphology associated with cell 
toxicity and as a result the plaques were smaller.  Increasing concentrations of TCs did 
not decrease EGFP expression in vRG0 plaques when observed by fluorescence 
microscopy.   
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FIGURE 3.4.  EGFP expression is not repressed in cells infected with vRG0 in the 
presence of varying concentrations of the ATC-MgCl2 complex.  BS-C-1 cells 
infected with vRG0 in the presence of ATC-MgCl2 displayed typical CPE 2 DPI in 
concentrations of 20 mM MgCl2 or less.  However, cells infected with 100 mM of MgCl2 
exhibited morphology associated with toxicity and as a result a normal infection did not 
occur in comparison to lower concentrations (brightfield images not shown).  Regardless, 
EGFP expression by vRG0 was not repressed by ATC-MgCl2.   
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FIGURE 3.5.  RevTetR mutants lead to different EGFP expression levels in the 
absence of TCs.  BS-C-1 cells infected with the VACVs in the absence of TCs displayed 
typical CPE 2 DPI, and single isolated plaques were imaged by brightfield and 
fluorescence microscopy.  vRG5, vRG0 and vRGc plaques displayed similar high 
fluorescence levels.  The other recombinants exhibited decreasing levels of EGFP 
expression in the following order, vRG3 and vRG4 were equal followed by vRG2 and 



















FIGURE 3.6.  EGFP expression is repressed in the presence of increasing 
concentrations of TCs.  BS-C-1 cells were infected at an MOI of 1 with the VACVs in 
the absence or presence of TCs and imaged by fluorescence microscopy 2 DPI.  With the 
exception of vRG0, EGFP expression was repressed in all other recombinant VACVs, 
although not all expressed EGFP at high levels in the presence of TCs.   
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FIGURE 3.7.  EGFP expression is repressed in the presence of increasing 
concentrations of ATC when measured by fluorescence imaging quantification.  
Fluorescence levels of cells previously imaged (Figure 3.6) were quantified.  Cells 
infected with vRG1 to vRG5 show repression of EGFP expression with increasing 
concentrations of ATC.  vRG0 displayed minimal repression even at the highest 

















FIGURE 3.8.  EGFP expression is repressed in the presence of increasing 
concentrations of TET when measured by fluorescence imaging quantification.  
Fluorescence levels of cells previously imaged (Figure 3.6) were quantified.  Cells 
infected with vRG1 to vRG5 show repression of EGFP expression with increasing 
concentrations of TET.  vRG0 displayed minimal repression even at the highest 


















FIGURE 3.9.  EGFP expression is repressed in the presence of increasing 
concentrations of DOX when measured by fluorescence imaging quantification.  
Fluorescence levels of cells previously imaged (Figure 3.6) were quantified.  Cells 
infected with vRG1 to vRG5 show repression of EGFP expression with increasing 
concentrations of DOX.  Expression by vRG1, vRG2, vRG3, and vRG4 is repressible to 
the levels of the negative control WR.  vRG0 displayed minimal repression even at the 
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FIGURE 3.10.  EGFP expression is repressed in the presence of increasing 
concentrations of ATC when measured by a multiwell fluorescence reader.  In this 
preliminary study, BS-C-1 cells were infected at an MOI of 1 with the VACVs in the 
absence or presence of ATC and 2 DPI cells were fixed and quantified with a fluorometer.  
EGFP expression levels were repressed in the presence of increasing concentrations of 
















FIGURE 3.11.  EGFP expression is repressed in the presence of increasing 
concentrations of TET when measured by a multiwell fluorescence reader.  In this 
preliminary study, BS-C-1 cells were infected at an MOI of 1 with the VACVs in the 
absence or presence of TET and 2 DPI cells were fixed and quantified with a fluorometer.  
EGFP expression levels were repressed in the presence of increasing concentrations of 














FIGURE 3.12.  EGFP expression is repressed in the presence of increasing 
concentrations of DOX when measured by a multiwell fluorescence reader.  In this 
preliminary study, BS-C-1 cells were infected at an MOI of 1 with the VACVs in the 
absence or presence of DOX and 2 DPI cells were fixed and quantified with a 
fluorometer.  EGFP expression levels were repressed in the presence of increasing 
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FIGURE 3.13.  ATC represses EGFP expression in a dose response manner.  BS-C-1 
cells were infected at an MOI of 1 with the VACVs in the absence or presence of ATC 
and 2 DPI cells were fixed and quantified with a multiwell fluorescence reader.  EGFP 
expression levels were repressed in the presence of increasing concentrations of ATC.  
Error bars are SEM, n=2.   
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FIGURE 3.14.  TET represses EGFP expression in a dose response manner.  BS-C-1 
cells were infected at an MOI of 1 with the VACVs in the absence or presence of TET 
and 2 DPI cells were fixed and quantified with a multiwell fluorescence reader.  EGFP 
expression levels were repressed in the presence of increasing concentrations of TET.  
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FIGURE 3.15.  DOX represses EGFP expression in a dose response manner.  BS-C-
1 cells were infected at an MOI of 1 with the VACVs in the absence or presence of DOX 
and 2 DPI cells were fixed and quantified with a multiwell fluorescence reader.  EGFP 
expression levels were repressed in the presence of increasing concentrations of DOX.  
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VACV revTetR Mutations References 
vRG0 L17G L17G Scholz et al., 2004 
vRG1 Original rtTA E71K, D95N, L101S, G102D Gossen et al., 1995 
vRG2 Advanced rtTA (rtTA-M2) S12G, E19G, A56P, D148E, H179R Urlinger et al., 2000 
vRG3 rtTA-S2 E19G, A56P, D148E, H179R Urlinger et al., 2000 
vRG4 rtTA-M1 S12G, E19G, A56P Urlinger et al., 2000 
vRG5 rtTA-19/56R E19G, A56P Urlinger et al., 2000 
!
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